Lila Biologics, Inc.

Developing integrin platform of antagonists including alpha 5 beta 1 (α5β1) for Pulmonary Arterial Hypertension (PAH) and alpha V beta 6 (αvβ6) minibinder for Idiopathic Pulmonary Fibrosis and Cancer

Lila Biologics was spun out of the Institute for Protein Design by scientific founders Anindya Roy and Jake Kraft in 2022 to develop mini-protein inhibitors targeting the integrin family of receptors with high selectivity and affinity. Lila's integrin-targeted platform technology has a wide range of potential therapeutic applications (e.g., fibrosis, IBD, oncology, and immuno-oncology) and already have highly selective inhibitors targeting avb6, avb8, a5b1, and a lead on avb1 integrin. The team, joined by Sheila Gujrathi, MD (former CEO of Gossamer) is also identifying lung- and gut-restricted non-integrin targets that would benefit from selective and hyper stable binders.